Description: Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Home Page: www.auriniapharma.com
118 Avenue , 14315
Edmonton,
AB
T5L 4S6
Canada
Phone:
250 744 2487
Officers
| Name | Title |
|---|---|
| Mr. Peter S. Greenleaf M.B.A. | CEO & Director |
| Mr. Joseph M. Miller CPA | Chief Financial Officer |
| Mr. Matthew Maxwell Donley M.B.A. | Chief Operations Officer |
| Mr. Stephen P. Robertson | Executive Vice President of General Counsel |
| Ms. Andrea Levin Christopher | Head of the Corporate Communications & Investor Relations |
| Mr. Michael R. Martin | Chief Business Officer |
| Ms. Sue Evans | Senior Vice President of Global Regulatory Affairs |
| Dr. Gregory F. Keenan M.D. | Chief Medical Officer |
| Dr. Premchandran Ramiya Ph.D. | Senior Vice President of Manufacturing & Supply Chain |
| Ms. DeDe Sheel | Vice President of Investor Relation |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 12.5945 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.2023 |
| Price-to-Sales TTM: | 5.4887 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 300 |